neoadjuvant therapy-Sun Yat-sen University-non-small cell lung cancer

This is a multi-modality treatment regimen for locally advanced non-small cell lung cancer (NSCLC) being evaluated in a Phase II study led by Sun Yat-sen University. The regimen centers on the use of **iparomlimab and tuvonralimab (QL1706)**, a first-in-class bifunctional antibody (MabPair) that simultaneously targets Programmed Cell Death Protein 1 (PD-1) and Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4). In the neoadjuvant phase, QL1706 is combined with bevacizumab (an anti-VEGF antibody), thymosin alpha 1 (an immune modulator), and platinum-based chemotherapy (cisplatin with either albumin-bound paclitaxel or pemetrexed). This is followed by concurrent chemoradiotherapy and a consolidation phase involving QL1706, surufatinib (a VEGFR/FGFR/CSF-1R inhibitor), and thymosin alpha 1. The regimen aims to enhance pathological complete response rates and improve long-term survival in patients with stage III NSCLC.

Other names

Dual Immune Checkpoint Blockade in Locally Advanced NSCLC